Luspatercept,epoetin alfa,Imetelstat
bms,Geron Corporation
['mds', 'lusp', '$gern', '$bmy']
major breakthrough in lower risk mds treatment landscape. evolution from esas to targeted therapies- luspatercept to become soc in 1l (epo&lt;500); imetelstat in 2l and 1l (epo&gt; 500) $gern $bmy #asco2023
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.